| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 320.25B | 317.24B | 290.02B | 248.55B | 234.55B | 247.75B | 
| Gross Profit | 183.74B | 182.40B | 160.16B | 132.14B | 130.06B | 145.85B | 
| EBITDA | 64.81B | 64.36B | 57.64B | 36.34B | 43.11B | 53.95B | 
| Net Income | 33.91B | 34.86B | 31.73B | 19.27B | 26.48B | 53.35B | 
| Balance Sheet | ||||||
| Total Assets | 0.00 | 497.85B | 450.72B | 398.90B | 339.22B | 338.54B | 
| Cash, Cash Equivalents and Short-Term Investments | 82.36B | 82.36B | 63.25B | 62.24B | 45.58B | 56.21B | 
| Total Debt | 0.00 | 82.63B | 66.48B | 52.86B | 32.79B | 53.39B | 
| Total Liabilities | -326.47B | 171.38B | 152.21B | 130.38B | 93.48B | 119.25B | 
| Stockholders Equity | 326.47B | 326.53B | 298.43B | 268.40B | 245.76B | 219.30B | 
| Cash Flow | ||||||
| Free Cash Flow | 0.00 | 19.57B | -11.27B | -3.34B | 23.12B | 14.55B | 
| Operating Cash Flow | 0.00 | 39.25B | 24.35B | 23.87B | 50.16B | 33.29B | 
| Investing Cash Flow | 0.00 | -18.76B | -42.56B | -39.78B | -32.12B | 5.99B | 
| Financing Cash Flow | 0.00 | 1.20B | 8.00B | 18.14B | -29.69B | -13.65B | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | ₹630.26B | 18.58 | ― | 0.36% | 7.76% | -2.84% | |
| ― | ₹663.10B | 29.02 | ― | 0.83% | 4.49% | 11.22% | |
| ― | ₹877.48B | 23.70 | ― | 0.61% | 12.40% | 63.16% | |
| ― | ₹993.45B | 21.73 | ― | 1.10% | 14.52% | 9.46% | |
| ― | ₹485.71B | 95.39 | ― | 0.13% | 25.83% | 421.20% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | ₹522.88B | 69.69 | ― | 0.14% | 10.99% | ― | 
Aurobindo Pharma Ltd has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma Chile SpA, through its existing subsidiary Helix Healthcare B.V. This strategic move aims to expand Aurobindo’s pharmaceutical business into the Chilean market, enhancing its global footprint. The incorporation involves a 100% cash subscription to the share capital, with no governmental or regulatory approvals required, indicating a smooth entry into the Chilean market.
Aurobindo Pharma Ltd has announced the incorporation of a new wholly owned subsidiary, Eugia Pharma Chile SpA, in Chile through its stepdown subsidiary, Eugia Pharma B.V. This strategic move aims to expand Aurobindo’s pharmaceutical business in the Chilean market, enhancing its international footprint and potentially increasing its market share in the region. The incorporation involves a 100% cash subscription to the share capital, with no governmental or regulatory approvals required, indicating a streamlined expansion process.
Aurobindo Pharma Ltd has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD., through its subsidiary Helix Healthcare B.V. This strategic move aims to expand the company’s pharmaceutical products business in Malaysia, enhancing its market footprint in the region. The new entity is fully owned by Aurobindo Pharma, with an initial investment of RM 400,000, and is expected to bolster the company’s operations and competitive positioning in the Southeast Asian pharmaceutical market.
Aurobindo Pharma Limited announced the completion of a US FDA inspection at Unit-I of its wholly owned subsidiary, Apitoria Pharma Private Limited, located in Telangana, India. The inspection concluded with a ‘Form 483’ issued containing five procedural observations, but no data integrity issues were found. The company stated that these observations will not impact its financials or operations, reaffirming its commitment to maintaining high-quality manufacturing standards.
Aurobindo Pharma Ltd has announced its participation in an upcoming virtual investor conference organized by Centrum Broking on August 20, 2025. This engagement reflects the company’s ongoing efforts to maintain transparency with stakeholders and investors, although no unpublished price-sensitive information will be disclosed during the meeting.